1. Home
  2. JQC vs NGNE Comparison

JQC vs NGNE Comparison

Compare JQC & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

JQC

Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

SELL

Current Price

$4.47

Market Cap

705.1M

Sector

Finance

ML Signal

SELL

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$24.42

Market Cap

744.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JQC
NGNE
Founded
2003
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
705.1M
744.9M
IPO Year
2003
2014

Fundamental Metrics

Financial Performance
Metric
JQC
NGNE
Price
$4.47
$24.42
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
★ $77.88
AVG Volume (30 Days)
★ 822.1K
293.9K
Earning Date
01-01-0001
11-12-2026
Dividend Yield
★ 11.13%
N/A
EPS Growth
N/A
★ 0.93
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$4.48
$15.93
52 Week High
$5.18
$43.66

Technical Indicators

Market Signals
Indicator
JQC
NGNE
Relative Strength Index (RSI) 33.62 39.84
Support Level N/A $18.68
Resistance Level $4.88 $29.16
Average True Range (ATR) 0.05 2.16
MACD -0.01 0.38
Stochastic Oscillator 8.00 38.58

Price Performance

Historical Comparison
JQC
NGNE

About JQC Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

Nuveen Credit Strategies Income Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. The fund meets its investment objectives by investing its managed assets in senior secured and second lien loans, and its managed assets across the capital structure of companies (including equity securities) with a primary emphasis on high yield bonds, convertible securities and other forms of income-producing securities.

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Share on Social Networks: